These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19429730)

  • 61. Deferred treatment for clinically localized prostate cancer.
    Adolfsson J
    Eur J Surg Oncol; 1995 Aug; 21(4):333-6. PubMed ID: 7664892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Elevated distress, race/ethnicity age, education, income, and type of cancer: It is complicated.
    Montel S; Clark K; Loscalzo M
    Psychooncology; 2018 Apr; 27(4):1334-1337. PubMed ID: 29168300
    [No Abstract]   [Full Text] [Related]  

  • 63. Optimizing the management of prostate cancer in senior adults: call to action.
    Fitzpatrick JM
    Oncologist; 2012; 17 Suppl 1(Suppl 1):1-3. PubMed ID: 23015678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patient Preferences for Communication of Life Expectancy in Prostate Cancer Treatment Consultations.
    Daskivich TJ; Gale R; Luu M; Khodyakov D; Anger JT; Freedland SJ; Spiegel B
    JAMA Surg; 2022 Jan; 157(1):70-72. PubMed ID: 34757389
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Words of Wisdom. Re: Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
    Kattan MW
    Eur Urol; 2015 Dec; 68(6):1098. PubMed ID: 26545570
    [No Abstract]   [Full Text] [Related]  

  • 66. Comorbidity assessment in localized prostate cancer: a systematic review protocol.
    Moretti K; Coombe R
    JBI Database System Rev Implement Rep; 2017 Apr; 15(4):942-947. PubMed ID: 28398980
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment of prostate cancer according to life expectancy, comorbidity and clinical practice guidelines].
    Pérez-Gracia JL; Rodríguez Ruiz ME; Fusco JP; Gúrpide A
    An Sist Sanit Navar; 2015; 38(3):463-4. PubMed ID: 26786375
    [No Abstract]   [Full Text] [Related]  

  • 68. The Importance of Accurate Life Expectancy Prediction in Men with Prostate Cancer.
    Daskivich TJ
    Eur Urol; 2015 Nov; 68(5):766-7. PubMed ID: 25913392
    [No Abstract]   [Full Text] [Related]  

  • 69. Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    Griebling TL
    J Urol; 2017 Oct; 198(4):723. PubMed ID: 28905752
    [No Abstract]   [Full Text] [Related]  

  • 70. Prostate cancer: Estimated life expectancy: integration of age and comorbidities.
    Heidenreich A; Pfister D
    Nat Rev Urol; 2016 Nov; 13(11):634-635. PubMed ID: 27754470
    [No Abstract]   [Full Text] [Related]  

  • 71. Re: years of potential life lost caused by prostate cancer deaths in the United States-projection from 2004 through 2050.
    Walsh PC
    J Urol; 2011 Jan; 185(1):141-2. PubMed ID: 22082920
    [No Abstract]   [Full Text] [Related]  

  • 72. A different perspective regarding prostate-specific antigen testing.
    Casner PR
    Arch Intern Med; 2012 Jul; 172(14):1110-1. PubMed ID: 22825064
    [No Abstract]   [Full Text] [Related]  

  • 73. A different perspective regarding prostate-specific antigen testing: in reply.
    Grady D; Redberg RF
    Arch Intern Med; 2012 Jul; 172(14):1111. PubMed ID: 22825065
    [No Abstract]   [Full Text] [Related]  

  • 74. Reply by Authors.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2020 Feb; 203(2):421. PubMed ID: 31596670
    [No Abstract]   [Full Text] [Related]  

  • 75. Editorial Comment.
    Gore JL
    J Urol; 2019 Sep; 202(3):524. PubMed ID: 31180280
    [No Abstract]   [Full Text] [Related]  

  • 76. The role of health literacy in cancer care: A mixed studies systematic review.
    Holden CE; Wheelwright S; Harle A; Wagland R
    PLoS One; 2021; 16(11):e0259815. PubMed ID: 34767562
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review.
    Cotter AR; Vuong K; Mustelin L; Yang Y; Rakhmankulova M; Barclay CJ; Harris RP
    BMJ Open; 2017 Dec; 7(12):e017565. PubMed ID: 29237653
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
    Lunardi P; Ploussard G; Grosclaude P; Roumiguié M; Soulié M; Beauval JB; Malavaud B
    World J Urol; 2017 Apr; 35(4):587-593. PubMed ID: 27443847
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.
    Xu J; Janisse J; Ruterbusch JJ; Ager J; Liu J; Holmes-Rovner M; Schwartz KL
    Ann Fam Med; 2016 May; 14(3):208-14. PubMed ID: 27184990
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.
    Basu A
    J Appl Econ (Chichester Engl); 2014; 29(4):671-691. PubMed ID: 25620844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.